Furthermore, we investigated the effect of Acclydine on IGF1 concentration, IGFBP3/IGF1 ratio, and CFS-related symptoms in a well-defined CFS population using validated outcome measures and a randomized double-blind placebo-controlled design. Here, IGFBP3 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.